Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 SEK | -4.52% | +4.41% | +8.07% |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 5.8 times its current sales, is high.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.07% | 3.27Cr | D+ | ||
+16.25% | 12TCr | B+ | ||
+19.31% | 11TCr | B+ | ||
+18.86% | 2.65TCr | B | ||
-23.33% | 1.94TCr | B+ | ||
-19.03% | 1.62TCr | A- | ||
-20.05% | 1.54TCr | B | ||
-46.14% | 1.52TCr | A- | ||
+63.66% | 1.49TCr | C+ | ||
+4.31% | 1.35TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MVIR B Stock
- Ratings Medivir AB